Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02731313
Other study ID # ML27940
Secondary ID
Status Completed
Phase N/A
First received March 24, 2016
Last updated April 2, 2016
Start date July 2012
Est. completion date October 2014

Study information

Verified date April 2016
Source Hoffmann-La Roche
Contact n/a
Is FDA regulated No
Health authority France: Commission Nationale de l'Informatique et des Libertés (CNIL)
Study type Observational

Clinical Trial Summary

The objective of this study is to assess concordance between two different laboratory methods for determination of human epidermal growth factor receptor 2 (HER-2) status in participants with gastric and gastro-esophageal junction carcinomas in routine practice compared to centralized analysis. Immunohistochemistry (IHC) and in situ hybridization (ISH) methods are compared in this study.


Recruitment information / eligibility

Status Completed
Enrollment 420
Est. completion date October 2014
Est. primary completion date October 2014
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- Tumor samples with histologically confirmed gastric or gastro-esophageal junction (GEJ) adenocarcinoma, any stage

- Samples with sufficient tumor material for centralized analysis

- Samples fixed and embedded in paraffin (formalin-fixed paraffin-embedded tissue [FFPET] samples).

Exclusion Criteria:

- Fixatives not allowed: Bouin's solution

Study Design

Observational Model: Case-Only, Time Perspective: Cross-Sectional


Related Conditions & MeSH terms


Intervention

Biological:
Trastuzumab
Trastuzumab was not administered in this study. This study informs future trastuzumab treatment decisions.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Hoffmann-La Roche

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Kappa Coefficient of Correlation of Human Epidermal Growth Factor Receptor 2 (HER-2) Status Between Local and Centralized Laboratory Assessments At enrollment No
Secondary Cancer Characteristics: Percentage of Samples with Initial Location of Adenocarcinoma in Stomach versus Esogastric Location At enrollment No
Secondary Cancer Characteristics: Percentage of Samples in Each of the Histologic Type Lauren's Classifications, Including Diffuse Type, Intestinal and Mixed At enrollment No
Secondary Cancer Characteristics: Percentage of Samples in Each of the Tumor-Node-Metastasis (TNM) Stages At enrollment No
Secondary Weighted Kappa Coefficient for Correlation Between Immunohistochemistry (IHC) 4B5 and Silver in situ Hybridization (SISH) Techniques for HER-2 Testing in Centralized Laboratories At enrollment No